DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/00af33/united_states_phar) has
announced the addition of the "United States Pharmaceuticals and Healthcare
Report Q4 2009" report to their offering.
United States Pharmaceuticals and Healthcare Report provides industry
professionals and strategists, corporate analysts, pharmaceutical associations,
government departments and regulatory bodies with independent forecasts and
competitive intelligence on the United States' pharmaceuticals and healthcare
industry.
Despite a downturn in growth rates in the US pharmaceuticals & healthcare
markets, the country remains a core component for any company looking to achieve
global success. Healthcare spending in 2008 reached US$2.3trn, while sales of
pharmaceuticals topped US$309bn.
For BMI's US Pharmaceuticals & Healthcare Report Q409, our new 10-year Drug
Expenditure Model has been introduced, giving a longer-term view of potential
for sales. By 2018 BMI forecasts that pharmaceutical expenditure will be
approaching US$400bn, representing a compound annual growth rate (CAGR) of 2.5%.
This, combined with the US's strong regulatory environment, stable political and
economic environment and country structure-related opportunities mean that the
country is ranked first globally within our Business Environment Ratings.
Much is currently at stake in the US pharmaceutical & healthcare industry.
President Barack Obama's healthcare reform is set to dramatically change the
industry landscape over the next few years. Among the proposals are: the
possible introduction of a government health insurer, which would place
significant downward pressures on prices; reviewing the length of exclusivity
for biologics and entry for biosimilars, which could tilt the balance of generic
and patented market growth; the level of prescription coverage enacted under any
universal insurance model; and the introduction of re-imported drug legislation.
Patent expiries for many high value products are set to significantly erode
sales for many major pharmaceutical companies. However, due to the complexity of
patent files and litigation efforts, calculating the exact entry for generic
medicines can be troublesome. The possible ban of pay-to-delay settlements and
authorised generics could also provide a major downside for patented drugs. The
shape of economic recovery in the US will also have a major bearing on market
dynamics, particularly in the case of over-the-counter (OTC) medicines or
prescription drugs, which require substantial co-payments.
The epidemiological profile of the US resembles that of many developed states.
BMI's Burden of Disease Database (BoDD) reveals that of the 37.76mn
disability-adjusted life years (DALYs) lost to all diseases and injuries in
2008, just 5.13% were accountable to communicable diseases. This is fairly
typical for a developed state and is a reflection of the US's generally high
access to basic medical care and the effects of Westernised lifestyles causing
an increase in the burden of non-communicable diseases, despite beneficial
developments in medicine and medical technology.
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Business Environment Ratings
US - Market Summary
Regulatory Regime
Industry Developments
Industry Forecast Scenario
Competitive Landscape
Company Profiles
BMI Methodology
Companies Mentioned:
* Pfizer
* GlaxoSmithKline (GSK)
* Merck & Co
* Eli Lilly
* Amgen
* Watson Pharmaceuticals
For more information visit
http://www.researchandmarkets.com/research/00af33/united_states_phar
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Copyright Business Wire 2009
